Michael MakangaSrivicha KrudsoodEuropean & Developing Countries Clinical Trials PartnershipMahidol University2018-09-132018-09-132009-10-21Malaria Journal. Vol.8, No.SUPPL. 1 (2009)147528752-s2.0-70350031256https://repository.li.mahidol.ac.th/handle/20.500.14594/27644Current World Health Organization (WHO) guidelines for the treatment of uncomplicated falciparum malaria recommend the use of artemisinin-based combination therapy (ACT). Artemether/lumefantrine is an ACT prequalified by the WHO for efficacy, safety and quality, approved by Swissmedic in December 2008 and recently approved by the USA FDA. Coartem® is a fixed-dose combination of artemether and lumefantrine. Its two components have different modes of action that provide synergistic anti-malarial activity. It is indicated for the treatment of infants, children and adults with acute, uncomplicated infection due to Plasmodium falciparum or mixed infections including P. falciparum. A formulation with improved palatability has been developed especially for children (Coartem® Dispersible), which rapidly disperses in a small amount of water for ease of administration. The efficacy of the six-dose regimen of artemether/lumefantrine has been confirmed in many different patient populations around the world, consistently achieving 28-day PCR (polymerase chain reaction)-corrected cure rates of >95% in the evaluable population, rapidly clearing parasitaemia and fever, and demonstrating a significant gametocidal effect, even in areas of widespread parasite resistance to other antimalarials. © 2009 Makanga and Krudsood; licensee BioMed Central Ltd.video/youtubeMahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS10.1186/1475-2875-8-S1-S5